Compare Stocks → This company has increased its dividend every year for 54 years (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYTRNASDAQ:LIFENASDAQ:OTLKNASDAQ:TROVNASDAQ:TTNP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsLIFEaTyr Pharma$1.61-0.6%$1.85$1.08▼$2.70$109.39M1.25513,836 shs96,573 shsOTLKOutlook Therapeutics$8.13-1.9%$8.61$4.00▼$40.60$105.77M0.04545,951 shs188,485 shsTROVCardiff Oncology$4.37-2.9%$16.75$0.70▼$3.46$48.12M1.04648,892 shs832,218 shsTTNPTitan Pharmaceuticals$7.32+3.1%$7.34$5.00▼$16.60$6.69M1.3311,859 shs654 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTRLadRx0.00%0.00%0.00%0.00%0.00%LIFEaTyr Pharma+1.89%-7.95%-19.00%+8.00%-13.37%OTLKOutlook Therapeutics-3.72%-8.30%+11.95%+18.77%-63.96%TROVCardiff Oncology-4.79%-25.81%-15.47%+199.32%+191.33%TTNPTitan Pharmaceuticals0.00%-0.84%-3.27%+15.45%-55.35%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/ALIFEaTyr Pharma1.9471 of 5 stars3.43.00.00.03.21.70.0OTLKOutlook Therapeutics3.0064 of 5 stars4.42.00.00.02.91.70.6TROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTRLadRxN/AN/AN/AN/ALIFEaTyr Pharma2.75Moderate Buy$23.671,369.98% UpsideOTLKOutlook Therapeutics2.88Moderate Buy$46.43471.03% UpsideTROVCardiff OncologyN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest TTNP, OTLK, CYTR, LIFE, and TROV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.001/25/2024OTLKOutlook TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$31.401/25/2024OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$40.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTRLadRxN/AN/AN/AN/AN/AN/ALIFEaTyr Pharma$353K309.87N/AN/A$1.54 per share1.05OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/ATROVCardiff Oncology$250K192.47N/AN/A$0.94 per share4.65TTNPTitan Pharmaceuticals$1K6,690.48N/AN/A$8.82 per share0.83Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/ALIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)TROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ATTNPTitan Pharmaceuticals-$5.57M-$8.20N/A∞N/A-2,014.71%-165.90%-105.75%5/20/2024 (Estimated)Latest TTNP, OTLK, CYTR, LIFE, and TROV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/A2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTRLadRxN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTRLadRxN/AN/AN/ALIFEaTyr Pharma0.026.276.27OTLKOutlook TherapeuticsN/A0.440.44TROVCardiff Oncology0.122.372.37TTNPTitan PharmaceuticalsN/A5.555.55OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTRLadRxN/ALIFEaTyr Pharma61.72%OTLKOutlook Therapeutics11.20%TROVCardiff Oncology9.99%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipCYTRLadRxN/ALIFEaTyr Pharma3.70%OTLKOutlook Therapeutics5.30%TROVCardiff Oncology0.60%TTNPTitan Pharmaceuticals24.93%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableLIFEaTyr Pharma5667.94 million65.43 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTTNPTitan Pharmaceuticals4914,000686,000OptionableTTNP, OTLK, CYTR, LIFE, and TROV HeadlinesSourceHeadlineTitan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.comamericanbankingnews.com - April 15 at 2:14 AMLexeo Therapeutics (NASDAQ:LXEO) and Titan Pharmaceuticals (NASDAQ:TTNP) Critical Contrastamericanbankingnews.com - April 13 at 1:30 AM2005 Nissan Titanautoblog.com - March 25 at 4:09 AMTitan Pharmaceuticals Inc (TTNP)uk.investing.com - March 2 at 9:17 AMTitan Pharmaceuticals, Inc. (TN70.F)au.finance.yahoo.com - February 20 at 2:08 PMTitan Pharmaceuticals Inc TTNPmorningstar.com - February 3 at 2:27 PMTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteriafinanznachrichten.de - January 26 at 9:07 PMTitan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteriafinance.yahoo.com - January 25 at 7:32 PMTitan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and Datesbenzinga.com - January 10 at 1:05 PMTitan Pharmaceuticals: Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibitscbonds.com - December 30 at 10:29 AMTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and Ratiofinanznachrichten.de - December 29 at 8:01 AMBarbie, the Titan submersible and everything else we Googled in 2023washingtonpost.com - December 28 at 8:29 PMTitan Pharmaceuticals Announces Reverse Stock Split and Ratiofinance.yahoo.com - December 28 at 8:29 PMUntitled Attack on Titan Codes (December 2023)twinfinite.net - December 27 at 3:54 PM2023 Nissan Titan XD Reviewautoblog.com - December 27 at 3:54 PMAttack on Titan Revolution Codes (December 2023)twinfinite.net - December 20 at 10:44 PMTitan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directorsfinance.yahoo.com - October 16 at 8:58 PMMore presumed human remains recovered from imploded Titan submersibletoday.com - October 14 at 10:10 AMTitan Pharmaceuticals reports $9.5M private placement of convertible preferred stockseekingalpha.com - September 18 at 11:34 AMTitan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stockfinance.yahoo.com - September 18 at 11:34 AMUnveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guidefinance.yahoo.com - August 28 at 5:04 PMTitan Pharmaceuticals: Q2 Earnings Snapshotstamfordadvocate.com - August 15 at 5:27 PMTitan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approvalthestreet.com - August 13 at 6:28 PMTitan Pharmaceuticals sells certain ProNeura assets to Fedsonpharmabiz.com - July 29 at 5:54 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideBlackstone’s $10 Billion Bet on Property Prices Going UpApril 11, 2024 7:30 AMView Blackstone’s $10 Billion Bet on Property Prices Going UpAll Headlines Company DescriptionsLadRxNASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Cardiff OncologyNASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.Titan PharmaceuticalsNASDAQ:TTNPTitan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.